First Brands Group debt targeted by Apollo Global Management - report
Investing.com - Citizens JMP analyst reiterated a Market Perform rating on Adicet Bio Inc. (NASDAQ:ACET) on Tuesday. According to InvestingPro data, the stock is trading at $0.76, with analysts’ price targets ranging from $4 to $8, reflecting significant upside potential despite recent volatility.
The research firm maintained its neutral stance on the clinical-stage biotechnology company, which focuses on developing allogeneic gamma delta T cell therapies for cancer and other diseases. While the company maintains a strong liquidity position with a current ratio of 7.48 and more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn remains a key concern.
Citizens JMP identified ADI-001 as a key value driver for Adicet Bio, with initial clinical data for autoimmune disease expected in the second half of 2025.
The firm also highlighted ADI-212 for prostate cancer as another important catalyst, noting that an Investigational New Drug (IND) submission is planned for the first quarter of 2026.
These upcoming milestones represent significant development points in Adicet Bio’s clinical pipeline as the company advances its cell therapy candidates toward potential regulatory approvals.
In other recent news, Adicet Bio has made several noteworthy announcements. The company reported its second-quarter 2025 financial results and shared strategic updates, including halting the development of ADI-270 for clear cell renal cell carcinoma and implementing a 30% workforce reduction. This move is expected to extend Adicet Bio’s cash runway into the fourth quarter of 2026. Additionally, Adicet Bio has dosed its first systemic sclerosis patient in the second cohort of its Phase 1 clinical trial for ADI-001, targeting autoimmune diseases. Preliminary clinical data from this trial is anticipated in the second half of 2025. Analyst firm H.C. Wainwright has initiated coverage on Adicet Bio with a Buy rating and a $4.00 price target, focusing on the company’s ADI-270 therapy. Meanwhile, Citizens JMP analyst Reni Benjamin has reiterated a Market Perform rating on the company’s stock. These developments highlight Adicet Bio’s ongoing efforts in clinical trials and strategic financial planning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.